A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Than 6 Years Old
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Givinostat (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Italfarmaco
- 24 Jan 2025 Status changed from not yet recruiting to recruiting.
- 16 Jan 2025 New trial record